Drug · Small Molecule

Panobinostat

CI-DRUG-00000456Explore in graph →NCIt C66948 CHEMBL483254 CIViC Approved

Regulatory

Approvals (1)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

emaRegulatory1 approval record · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
EU EMA	Multiple Myeloma	Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent. Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.	approved	Aug 28, 2015	ema

Data updated 14 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	2	1	3	116	1	EU	Aug 28, 2015	Mar 1, 2003
Multiple Myeloma	Approved	Phase 3	0	0	1	28	1	EU	Aug 28, 2015	Mar 1, 2003
Non-Hodgkin Lymphoma	Approved	Phase 3	0	0	1	43	1	EU	Aug 28, 2015	Mar 1, 2003
Leukemia	Phase4	Phase 4	1	0	1	20	0	—	—

Curated evidence

Clinical evidence (8)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–8 of 8 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CSF1R Fusion1
Panobinostat	B Lymphoblastic Leukemia/Lymphoma

Clinical trials

Trials with this intervention (119)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 119 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02386800	CINC424A2X01B Rollover Protocol	active not recruiting	Phase 4	279	Novartis PharmaceuticalsINDUSTRY	25	Aug 20, 2026	clinicaltrials
NCT04804709	Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)	terminated	Phase 1

Molecule

Record

Kind: Small Molecule
Mechanism: Histone deacetylase inhibitor
Targets: 11 genes
Aliases: (2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide, Faridak, Farydak, LBH 589, LBH-589, LBH589, Panobinostat, Panobinostat hydrate

Data updated 24 hours agoSource updated unknown

Identifiers

Codes (2)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01XH03	Antineoplastic agents
EMA product	EMEA/H/C/003725	Farydak

Regulatory status is jurisdiction-specific and time-bound. Nothing on this page is a treatment recommendation.